Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Accumulated Expenses (2021 - 2025)

Medicinova (MNOV) has disclosed Accumulated Expenses for 7 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a N/A change, with the full-year FY2025 number at $2.6 million, changed N/A from a year prior.
  • Accumulated Expenses was $2.6 million for Q4 2025 at Medicinova, up from $1.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.8 million in Q3 2022 to a low of $1.2 million in Q1 2025.
  • A 5-year average of $2.0 million and a median of $1.9 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 122.09% in 2022, then plummeted 51.18% in 2023.
  • Medicinova's Accumulated Expenses stood at $2.3 million in 2021, then surged by 65.72% to $3.8 million in 2022, then plummeted by 45.93% to $2.1 million in 2023, then dropped by 18.09% to $1.7 million in 2024, then soared by 54.62% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Accumulated Expenses are $2.6 million (Q4 2025), $1.9 million (Q3 2025), and $1.9 million (Q2 2025).